Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00000672 | An Efficacy Study of 2',3'-Dideoxyinosine (ddI) (BMY-40900) Administered Orally Twice Daily to Zidovudine Intolerant Patients With AIDS or AIDS-Related Complex | PHASE2 | COMPLETED | 660 | — | — | - | - | Mar 14, 2011 | 67 | United States, Puerto Rico |
| NCT00002360 | A Study Comparing Two Forms of Didanosine in HIV-infected Patients | PHASE1 | COMPLETED | 30 | — | — | Mar 1, 1999 | Mar 1, 1999 | Apr 14, 2011 | - | — |
| NCT00000669 | A Phase I Safety and Pharmacokinetics Study of 2',3'-Dideoxyinosine (ddI) Administered Twice Daily to Infants and Children With AIDS or Symptomatic HIV Infection | PHASE1 | COMPLETED | 25 | — | — | - | - | Aug 26, 2008 | 5 | United States |
| Name | Type | Description |
|---|---|---|
| Didanosine | DRUG | - |
Inclusion Criteria Concurrent Medication: Required: * Aerosolized pentamidine (300 mg every 4 weeks). In the event of physiological intolerance, alternative PCP prophylaxis may be trimethoprim/sulfamethoxazole 1 DS tab per day or dapsone 50 - 100 mg per day. Allowed: * Chronic suppressive treat...